4D pharma plc (DDDD.L)

103.00 +3.10 (+3.10%) At close: 4:35PM BST

4D pharma plc

9 Bond Court
5th Floor
Leeds LS1 2JZ
United Kingdom
44 11 3895 0130
http://www.4dpharmaplc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 92

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Duncan Joseph Peyton	CEO & Exec. Director	102k	N/A	1970
Dr. Alexander James Stevenson	Chief Scientific Officer & Exec. Director	102k	N/A	1972
Mr. John W. Beck CPA, CPA	Chief Financial Officer	N/A	N/A	1960
Fay Weston	Head of Investor Relations	N/A	N/A	N/A
Mr. Adrian Murray	Gen. Counsel (Interim)	N/A	N/A	N/A
Mr. Glenn Dourado	Chief Bus. Officer	N/A	N/A	N/A
Mr. Richard Avison	Group Fin. Director	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Corporate governance

4D pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.